logo-loader

Medgenics' new team fundamental to firm's continued success, says chairman

Published: 09:04 16 Sep 2013 EDT

no_picture_pai

Medgenics (LON:MEDG, NYSE:MDGN), which is developing Biopump platform technology, has unveiled a new executive team with a host of industry experience.

It comes as the founder and former president and chief executive Andrew Pearlman retired as of Friday last week (September 13).

He is continuing to serve on the board and as a senior advisor to the company.

Michael Cola, most recently president of Shire's specialty pharma business, becomes president and chief executive.

Dr John Leaman, who brings more than a decade of corporate strategy, finance, venture capital and M&A experience in the life sciences industry, is chief financial officer.

Dr Garry Neil becomes Global Head of Research and Development.

Neil has more than 30 years of clinical development experience in the life sciences industry.  Most recently he was a partner at Apple Tree Partners, a life sciences private equity fund.

Chairman Sol J Barer said: "Collectively, the new team's relevant experience and knowledge is impressive and will be integral to Medgenics' continued success."

He added: "On behalf of the board and the entire staff at Medgenics, I extend deepest gratitude to Andy Pearlman for his many contributions to our company.  Andy has dedicated more than a decade to the development of the Biopump technology, and it is through his efforts and leadership that we have such a strong foundation."

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 23 minutes ago